Phase 3 Uveitis Trial, Not Yet Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are between 18 and 50 years old.
• You have been diagnosed with Behçet's Disease using the standard international diagnostic criteria (ISG criteria).
• You have not previously had blood vessel complications from Behçet's Disease, or you have not been treated with immune-suppressing medicines for blood vessel complications.
• You have been diagnosed with a blood clot in a vein in your leg or lower body within the last 14 days before joining the study.
• Your blood clot has been confirmed by ultrasound, a special X-ray (venography), CT scan, or MRI scan showing specific signs of a clot.
• If you are a woman who could become pregnant, you must not be pregnant or breastfeeding, and you must be using effective birth control, be past menopause (no periods for at least 1 year), or have had a surgical procedure to prevent pregnancy.
• You are able to give written consent and follow the study's requirements.

Who may not be able to join:

• You have any abnormal bulging of a blood vessel (aneurysm) anywhere in your body.
• You have another serious long-term illness besides Behçet's Disease.
• You have previously had a bad reaction or intolerance to the medication Rivaroxaban.
• You have taken immune-suppressing medicines (such as azathioprine, cyclosporine, or certain biological medicines) within the last 6 months.
• You have taken steroid medicines (such as cortisone) for more than 3 months for Behçet's Disease skin or mouth symptoms.
• You have already received blood-thinning injections (such as heparin) for more than 48 hours, or more than one dose of warfarin-type medicines, before joining the study.
• You have already had a procedure to remove the clot, a filter placed in a large vein, or clot-dissolving treatment for your current clot.
• You are planning to receive a live vaccine within 30 days of joining the study.
• You have a significant uncontrolled illness affecting the heart, lungs, liver, kidneys, blood, gut, nerves, or an active infection or cancer that could affect the study results.
• You are due to have surgery or have another medical condition that the study doctor feels makes you unsuitable for the trial.
• You have had cancer in the last 5 years (with some exceptions for certain minor skin cancers or early-stage cervical changes — confirm with trial site).
• Your kidneys are not working well enough (confirmed by a blood test showing low kidney filtration rate below 30 ml/min).
• You have serious liver disease, such as hepatitis or cirrhosis, or abnormal liver blood test results.
• You are actively bleeding or are at high risk of bleeding, which would make blood-thinning treatment unsafe for you.
• Your blood pressure is very high and not under control (above 180/110 mmHg).
• You have severe anaemia (low red blood cell levels, confirmed by a blood test).
• You are pregnant, breastfeeding, or a woman of childbearing age not using contraception.
• You are taking certain strong medications that affect how the body processes Rivaroxaban (such as some HIV medicines, systemic ketoconazole, rifampin, carbamazepine, or phenytoin).
• You have taken part in another clinical drug trial within the last 30 days.
• Your life expectancy is less than 3 months.
• You have had a serious infection in the last 60 days, such as a heart valve infection, tuberculosis, or other opportunistic infections.
• You are currently misusing alcohol or substances, or have had a substance dependence problem within the last year.
• You have tested positive for Hepatitis B, Hepatitis C, or HIV.
• You have a known blood clotting disorder or significant abnormal blood test results (confirm with trial site).
• You have had suicidal behaviour in the last 6 months, or have had serious thoughts of suicide in the last 2 months (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.